which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...
Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease ... drugs, but potentially life-threatening. It could also face a strong challenge if Eisai and Biogen get approval ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational ...
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more ...
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...
(RTTNews) - CervoMed, Inc. (CRVO) announced Wednesday that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the ...
This is unnecessary pain and suffering that could be avoided if we were simply allowed to keep patients on the FDA-approved medication that was appropriate in the first place. Alzheimer’s ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...
NEW TONIGHT AT 11 TRIBE CLINICAL RESEARCH IN GREENVILLE HAS LAUNCHED A NEW TRIAL FOR A DRUG CENTERED ON ALZHEIMER’S PREVENTION ... LEADS THE DRUGS TO FDA APPROVAL. TCR NORMALLY SEES PATIENTS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback